Dornase alfa biobetter - Pharmsynthez/Xenetic Biosciences

Drug Profile

Dornase alfa biobetter - Pharmsynthez/Xenetic Biosciences

Alternative Names: Bronchozym; Polysialylated DNase; PSA-DNase; PulmoXen

Latest Information Update: 11 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmsynthez; Xenetic Biosciences
  • Developer Pharmsynthez
  • Class Antifibrotics; Biobetters; Recombinant proteins
  • Mechanism of Action Deoxyribonuclease 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
  • 17 Mar 2016 Phase I development is ongoing in Belarus, Russia and Ukraine
  • 31 Dec 2013 Phase-I clinical trials in Cystic fibrosis (in volunteers) in Russia, Ukraine and Belarus (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top